Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Lakewood-Amedex is not a business in the Graham sense yet; it is a pipeline. It has five employees, no reported revenue in fiscal Q1 2026 or Q2 2026, and its product candidates are still in clinical testing, including Nu-3 in Phase 2b for infected diabetic foot ulcers. That could be valuable if the science works, but I see no demonstrated competitive moat—only pipeline progress that I cannot verify from the supplied figures. Financial health is weak: in fiscal Q2 2026, the quarter ended 2026-06-30, net income was -$3.8 million versus -$655,943 in fiscal Q2 2025, and in fiscal Q1 2026 net income was -$923,291 versus -$539,617 a year earlier. Revenue is not reported. Trailing free cash flow is -$3.5 million, a -3.2% FCF yield on the $110.5 million market cap at the 2026-10-16 close. The balance sheet shows low D/E at 0.02, but FairStock-calculated negative ROE of -402.83% and ROCE of -139.40% confirm capital is being consumed. Valuation is awkward: at that close, P/E is -0.15 because EPS is -$3.90, while P/B is 0.29. A low price-to-book can look cheap, but book value here is not producing earnings. The Piotroski F-score of 2/9 is weak, though the Altman Z-score of 87.03 is a FairStock calculation that is not a normal safety signal for a pre-revenue biotech. The 52-week range of $0.37 to $10.00 shows speculative swings. I would treat this as a binary research bet, not a margin-of-safety compounder.

In plain English: Lakewood-Amedex is a small clinical-stage biotechnology company with five employees that is developing antimicrobial treatments, including a Phase 2b product for infected diabetic foot ulcers. It has no reported revenue, is losing money, and spent about $3.5 million more cash than it generated over the trailing year, so the underlying business looks weak today. At $0.58, the price may look low compared with the value of its assets on its books, but with continuing losses and no revenue it does not look conventionally cheap on business results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-16 close · note generated 2026-10-20 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer